Symbols / RNXT Stock $0.90 -5.09% RenovoRx, Inc.
RNXT (Stock) Chart
About
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
Stock Fundamentals
Scroll to Statements| Market Cap | 40.55M | Enterprise Value | 35.91M | Income | -11.17M | Sales | 1.12M | Book/sh | 0.15 | Cash/sh | 0.16 |
| Dividend Yield | — | Payout | 0.00% | Employees | 17 | IPO | — | P/E | — | Forward P/E | -7.50 |
| PEG | — | P/S | 36.11 | P/B | 6.08 | P/C | — | EV/EBITDA | -2.99 | EV/Sales | 31.98 |
| Quick Ratio | 3.65 | Current Ratio | 4.02 | Debt/Eq | 3.91 | LT Debt/Eq | — | EPS (ttm) | -0.32 | EPS next Y | -0.12 |
| EPS Growth | — | Revenue Growth | 4.54% | Earnings | 2026-03-30 | ROA | -92.59% | ROE | -225.62% | ROIC | — |
| Gross Margin | 70.88% | Oper. Margin | -12.70% | Profit Margin | 0.00% | Shs Outstand | 45.05M | Shs Float | 40.90M | Short Float | 1.37% |
| Short Ratio | 1.21 | Short Interest | — | 52W High | 1.45 | 52W Low | 0.70 | Beta | 1.22 | Avg Volume | 325.15K |
| Volume | 375.65K | Target Price | $6.88 | Recom | Strong_buy | Prev Close | $0.95 | Price | $0.90 | Change | -5.09% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.88
Mean price target
2. Current target
$0.90
Latest analyst target
3. DCF / Fair value
$-2.57
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.90
Low
$3.00
High
$13.50
Mean
$6.88
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-09 | main | Ascendiant Capital | Buy → Buy | $14 |
| 2026-04-08 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2026-02-17 | main | Ascendiant Capital | Buy → Buy | $13 |
| 2025-11-21 | main | Ascendiant Capital | Buy → Buy | $13 |
| 2025-08-25 | main | Ascendiant Capital | Buy → Buy | $12 |
| 2025-06-05 | main | Ascendiant Capital | Buy → Buy | $12 |
| 2025-05-19 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-04-28 | main | Ascendiant Capital | Buy → Buy | $11 |
| 2025-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-27 | init | HC Wainwright & Co. | — → Buy | $3 |
| 2024-12-10 | main | Ascendiant Capital | Buy → Buy | $9 |
| 2024-09-12 | main | Ascendiant Capital | Buy → Buy | $8 |
| 2024-06-17 | init | Ascendiant Capital | — → Buy | $8 |
| 2024-02-02 | init | Alliance Global Partners | — → Buy | $4 |
| 2023-11-15 | down | Maxim Group | Buy → Hold | — |
| 2023-08-18 | main | Roth MKM | Buy → Buy | $13 |
| 2021-11-01 | init | Roth Capital | — → Buy | $16 |
| 2021-10-06 | init | Maxim Group | — → Buy | $15 |
- RenovoRx pancreatic cancer study tests more targeted chemo delivery - Stock Titan hu, 23 Apr 2026 12
- RenovoRx (RNXT) price target decreased by 15.63% to 6.88 - MSN hu, 23 Apr 2026 09
- $RNXT stock is up 14% today. Here's what we see in our data. - Quiver Quantitative hu, 08 Jan 2026 08
- RNXT (RenovoRx Inc.) narrowly tops Q4 2025 EPS estimates, falls slightly in immediate post-earnings trading. - Expert Momentum Signals - Cổng thông tin điện tử Tỉnh Sơn La hu, 23 Apr 2026 01
- RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance hu, 13 Nov 2025 08
- Fast Company ranks cancer-device maker RenovoRx No. 10 for innovation - Stock Titan Wed, 01 Apr 2026 07
- Insider Purchase: Chief Medical Officer of $RNXT Buys 12,000 Shares - Quiver Quantitative Wed, 17 Dec 2025 08
- RenovoRx Inc (RNXT) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance Wed, 12 Nov 2025 08
- Cancer device reaches 12 U.S. centers as RenovoRx readies trial finish - Stock Titan Mon, 30 Mar 2026 07
- RenovoRx (RNXT) CMO granted 621,727 options vesting through 2030 - Stock Titan ue, 07 Apr 2026 07
- $10M investor bet on RenovoRx cancer device and trial push - Stock Titan Wed, 18 Mar 2026 07
- RenovoRx (RNXT) CFO granted 80,000-share RSU-based stock award - Stock Titan ue, 07 Apr 2026 07
- RenovoRx (RNXT) CCO awarded 128,550 options at $0.98 exercise price - Stock Titan ue, 07 Apr 2026 07
- Pancreatic cancer scans show early response after artery-delivered chemo - Stock Titan ue, 14 Apr 2026 12
- Cancer drug-delivery device wins Japan patent allowance as RenovoRx expands - Stock Titan Wed, 08 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
1.12
+2511.63%
|
0.04
|
0.00
|
0.00
|
| Operating Revenue |
|
1.12
+2511.63%
|
0.04
|
0.00
|
0.00
|
| Cost Of Revenue |
|
0.33
|
0.00
|
0.00
|
—
|
| Reconciled Cost Of Revenue |
|
0.33
|
0.00
|
0.00
|
—
|
| Gross Profit |
|
0.80
+1751.16%
|
0.04
|
0.00
|
—
|
| Operating Expense |
|
13.31
+20.83%
|
11.01
-3.36%
|
11.40
+14.53%
|
9.95
|
| Research And Development |
|
6.27
+4.05%
|
6.03
+6.32%
|
5.67
+31.76%
|
4.30
|
| Selling General And Administration |
|
7.04
+41.10%
|
4.99
-12.93%
|
5.73
+1.42%
|
5.65
|
| General And Administrative Expense |
|
7.04
+41.10%
|
4.99
-12.93%
|
5.73
+1.42%
|
5.65
|
| Salaries And Wages |
|
3.27
+21.52%
|
2.69
+9.04%
|
2.47
+28.81%
|
1.92
|
| Other Gand A |
|
3.77
+64.04%
|
2.30
-29.56%
|
3.26
-12.64%
|
3.73
|
| Total Expenses |
|
13.63
+23.80%
|
11.01
-3.36%
|
11.40
+14.53%
|
9.95
|
| Operating Income |
|
-12.51
-14.05%
|
-10.97
+3.74%
|
-11.40
-14.53%
|
-9.95
|
| Total Operating Income As Reported |
|
-12.51
-14.04%
|
-10.97
+3.74%
|
-11.40
-14.53%
|
-9.95
|
| EBITDA |
|
-12.51
-14.03%
|
-10.97
+3.74%
|
-11.40
-14.60%
|
-9.94
|
| Normalized EBITDA |
|
-13.42
-5.35%
|
-12.74
+2.77%
|
-13.11
-31.79%
|
-9.94
|
| Reconciled Depreciation |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.01
|
| EBIT |
|
-12.51
-14.05%
|
-10.97
+3.74%
|
-11.40
-14.53%
|
-9.95
|
| Total Unusual Items |
|
0.92
-48.36%
|
1.77
+3.69%
|
1.71
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
0.92
-48.36%
|
1.77
+3.69%
|
1.71
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-11.17
-26.71%
|
-8.81
+13.86%
|
-10.23
-3.47%
|
-9.89
|
| Pretax Income |
|
-11.17
-26.72%
|
-8.81
+13.86%
|
-10.23
-3.47%
|
-9.89
|
| Net Non Operating Interest Income Expense |
|
0.43
+11.20%
|
0.38
+170.46%
|
-0.55
-1056.14%
|
0.06
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
—
|
| Net Interest Income |
|
0.43
+11.20%
|
0.38
+170.46%
|
-0.55
-1056.14%
|
0.06
|
| Interest Expense |
|
—
|
—
|
—
|
—
|
| Interest Income Non Operating |
|
0.43
+11.20%
|
0.38
|
—
|
0.06
|
| Interest Income |
|
0.43
+11.20%
|
0.38
|
—
|
0.06
|
| Other Income Expense |
|
0.92
-48.36%
|
1.77
+3.69%
|
1.71
+42625.00%
|
0.00
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
0.00
|
| Gain On Sale Of Security |
|
0.92
-48.36%
|
1.77
+3.69%
|
1.71
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-11.17
-26.72%
|
-8.81
+13.86%
|
-10.23
-3.47%
|
-9.89
|
| Net Income From Continuing Operation Net Minority Interest |
|
-11.17
-26.71%
|
-8.81
+13.86%
|
-10.23
-3.47%
|
-9.89
|
| Net Income From Continuing And Discontinued Operation |
|
-11.17
-26.71%
|
-8.81
+13.86%
|
-10.23
-3.47%
|
-9.89
|
| Net Income Continuous Operations |
|
-11.17
-26.72%
|
-8.81
+13.86%
|
-10.23
-3.47%
|
-9.89
|
| Normalized Income |
|
-12.08
-14.14%
|
-10.59
+11.35%
|
-11.94
-20.75%
|
-9.89
|
| Net Income Common Stockholders |
|
-11.17
-26.71%
|
-8.81
+13.86%
|
-10.23
-3.47%
|
-9.89
|
| Diluted EPS |
|
—
|
-0.40
+59.60%
|
-0.99
+9.17%
|
-1.09
|
| Basic EPS |
|
—
|
-0.40
+59.60%
|
-0.99
+9.17%
|
-1.09
|
| Basic Average Shares |
|
—
|
22.27
+116.42%
|
10.29
+13.69%
|
9.05
|
| Diluted Average Shares |
|
—
|
22.27
+116.42%
|
10.29
+13.69%
|
9.05
|
| Diluted NI Availto Com Stockholders |
|
-11.17
-26.71%
|
-8.81
+13.86%
|
-10.23
-3.47%
|
-9.89
|
| Total Other Finance Cost |
|
—
|
-0.38
-170.46%
|
0.55
+1056.14%
|
-0.06
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
8.10
-0.28%
|
8.12
+453.75%
|
1.47
-79.82%
|
7.26
|
| Current Assets |
|
7.89
+0.83%
|
7.83
+433.97%
|
1.47
-79.82%
|
7.26
|
| Cash Cash Equivalents And Short Term Investments |
|
7.02
-1.82%
|
7.15
+509.89%
|
1.17
-81.79%
|
6.44
|
| Cash And Cash Equivalents |
|
7.02
-1.82%
|
7.15
+509.89%
|
1.17
-73.29%
|
4.39
|
| Other Short Term Investments |
|
—
|
—
|
0.00
-100.00%
|
2.05
|
| Receivables |
|
0.14
+223.26%
|
0.04
|
0.00
|
—
|
| Accounts Receivable |
|
0.14
+223.26%
|
0.04
|
0.00
|
—
|
| Inventory |
|
0.19
|
0.00
|
—
|
—
|
| Finished Goods |
|
0.19
|
0.00
|
—
|
—
|
| Prepaid Assets |
|
0.32
-1.22%
|
0.33
+95.24%
|
0.17
|
—
|
| Current Deferred Assets |
|
—
|
0.00
-100.00%
|
0.10
|
0.00
|
| Other Current Assets |
|
0.22
-28.38%
|
0.30
+1162.50%
|
0.02
-97.09%
|
0.82
|
| Total Non Current Assets |
|
0.20
-30.34%
|
0.29
|
0.00
|
0.00
|
| Net PPE |
|
0.20
-30.34%
|
0.29
|
0.00
|
0.00
|
| Gross PPE |
|
0.20
-29.66%
|
0.29
|
0.00
|
0.00
|
| Accumulated Depreciation |
|
-0.00
|
0.00
|
0.00
|
—
|
| Properties |
|
—
|
—
|
—
|
0.00
|
| Machinery Furniture Equipment |
|
0.01
+16.67%
|
0.01
|
0.00
|
—
|
| Other Properties |
|
0.19
-31.65%
|
0.28
|
—
|
—
|
| Leases |
|
—
|
—
|
—
|
0.00
|
| Non Current Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
2.67
-26.57%
|
3.64
-18.50%
|
4.47
+305.26%
|
1.10
|
| Current Liabilities |
|
1.96
+2.78%
|
1.91
+62.47%
|
1.18
+6.62%
|
1.10
|
| Payables And Accrued Expenses |
|
1.11
+8.09%
|
1.03
-6.73%
|
1.10
+75.44%
|
0.63
|
| Payables |
|
0.80
+36.35%
|
0.59
+4.46%
|
0.56
+5.06%
|
0.53
|
| Accounts Payable |
|
0.80
+36.35%
|
0.59
+4.46%
|
0.56
+5.06%
|
0.53
|
| Current Accrued Expenses |
|
0.31
-29.55%
|
0.44
-18.37%
|
0.54
+479.57%
|
0.09
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.75
-8.45%
|
0.82
+989.33%
|
0.07
-84.21%
|
0.47
|
| Current Debt And Capital Lease Obligation |
|
0.10
+59.09%
|
0.07
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.10
+59.09%
|
0.07
|
0.00
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.71
-58.93%
|
1.73
-47.40%
|
3.29
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
0.11
-49.53%
|
0.21
|
0.00
|
—
|
| Long Term Capital Lease Obligation |
|
0.11
-49.53%
|
0.21
|
0.00
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
5.42
+21.08%
|
4.48
+249.27%
|
-3.00
-148.68%
|
6.16
|
| Common Stock Equity |
|
5.42
+21.08%
|
4.48
+249.27%
|
-3.00
-148.68%
|
6.16
|
| Capital Stock |
|
0.00
+100.00%
|
0.00
+100.00%
|
0.00
+0.00%
|
0.00
|
| Common Stock |
|
0.00
+100.00%
|
0.00
+100.00%
|
0.00
+0.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
36.61
+52.34%
|
24.03
+124.76%
|
10.69
+17.54%
|
9.10
|
| Ordinary Shares Number |
|
36.61
+52.34%
|
24.03
+124.76%
|
10.69
+17.54%
|
9.10
|
| Additional Paid In Capital |
|
66.81
+22.14%
|
54.70
+42.42%
|
38.40
+2.91%
|
37.32
|
| Retained Earnings |
|
-61.39
-22.24%
|
-50.22
-21.29%
|
-41.41
-32.82%
|
-31.17
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
0.00
|
0.00
-100.00%
|
0.02
|
| Other Equity Adjustments |
|
—
|
—
|
—
|
0.02
|
| Total Equity Gross Minority Interest |
|
5.42
+21.08%
|
4.48
+249.27%
|
-3.00
-148.68%
|
6.16
|
| Total Capitalization |
|
5.42
+21.08%
|
4.48
+249.27%
|
-3.00
-148.68%
|
6.16
|
| Working Capital |
|
5.93
+0.20%
|
5.92
+1934.02%
|
0.29
-95.28%
|
6.16
|
| Invested Capital |
|
5.42
+21.08%
|
4.48
+249.27%
|
-3.00
-148.68%
|
6.16
|
| Total Debt |
|
0.21
-23.74%
|
0.28
|
0.00
|
—
|
| Capital Lease Obligations |
|
0.21
-23.74%
|
0.28
|
0.00
|
—
|
| Net Tangible Assets |
|
5.42
+21.08%
|
4.48
+249.27%
|
-3.00
-148.68%
|
6.16
|
| Tangible Book Value |
|
5.42
+21.08%
|
4.48
+249.27%
|
-3.00
-148.68%
|
6.16
|
| Derivative Product Liabilities |
|
0.60
-60.24%
|
1.52
-53.84%
|
3.29
|
0.00
|
| Interest Payable |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-10.97
-20.25%
|
-9.12
+11.05%
|
-10.26
-16.42%
|
-8.81
|
| Cash Flow From Continuing Operating Activities |
|
-10.97
-20.25%
|
-9.12
+11.05%
|
-10.26
-16.42%
|
-8.81
|
| Net Income From Continuing Operations |
|
-11.17
-26.71%
|
-8.81
+13.86%
|
-10.23
-3.47%
|
-9.89
|
| Depreciation Amortization Depletion |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.01
|
| Depreciation |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.01
|
| Depreciation And Amortization |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.01
|
| Other Non Cash Items |
|
0.09
+1157.14%
|
0.01
|
—
|
—
|
| Stock Based Compensation |
|
1.27
+7.92%
|
1.17
+8.91%
|
1.08
+67.39%
|
0.64
|
| Operating Gains Losses |
|
-0.92
+48.36%
|
-1.77
-3.69%
|
-1.71
|
—
|
| Gain Loss On Investment Securities |
|
-0.92
+48.36%
|
-1.77
-3.69%
|
-1.71
|
—
|
| Change In Working Capital |
|
-0.25
-188.21%
|
0.28
-53.72%
|
0.60
+41.36%
|
0.43
|
| Change In Receivables |
|
-0.10
|
0.00
|
—
|
—
|
| Changes In Account Receivables |
|
-0.10
|
0.00
|
—
|
—
|
| Change In Inventory |
|
-0.19
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
0.09
+156.25%
|
-0.16
-125.28%
|
0.63
+139.77%
|
0.26
|
| Change In Payables And Accrued Expense |
|
-0.05
-107.87%
|
0.66
+805.48%
|
0.07
-52.90%
|
0.15
|
| Change In Accrued Expense |
|
-0.27
-141.67%
|
0.64
+1282.61%
|
0.05
-70.32%
|
0.15
|
| Change In Payable |
|
0.21
+752.00%
|
0.03
-7.41%
|
0.03
+200.00%
|
0.01
|
| Change In Account Payable |
|
0.21
+752.00%
|
0.03
-7.41%
|
0.03
|
0.00
|
| Change In Other Current Assets |
|
0.00
+100.00%
|
-0.22
-118.81%
|
-0.10
-1222.22%
|
0.01
|
| Investing Cash Flow |
|
-0.00
+83.33%
|
-0.01
-100.59%
|
2.03
+200.00%
|
-2.03
|
| Cash Flow From Continuing Investing Activities |
|
-0.00
+83.33%
|
-0.01
-100.59%
|
2.03
+200.00%
|
-2.03
|
| Net PPE Purchase And Sale |
|
-0.00
+83.33%
|
-0.01
|
0.00
|
—
|
| Purchase Of PPE |
|
-0.00
+83.33%
|
-0.01
|
0.00
|
—
|
| Capital Expenditure |
|
-0.00
+83.33%
|
-0.01
|
—
|
—
|
| Capital Expenditure Reported |
|
—
|
—
|
—
|
0.00
|
| Net Investment Purchase And Sale |
|
—
|
0.00
-100.00%
|
2.03
+200.00%
|
-2.03
|
| Purchase Of Investment |
|
—
|
—
|
0.00
+100.00%
|
-8.00
|
| Sale Of Investment |
|
—
|
0.00
-100.00%
|
2.03
-65.95%
|
5.97
|
| Financing Cash Flow |
|
10.85
-28.26%
|
15.12
+201.88%
|
5.01
+11823.81%
|
0.04
|
| Cash Flow From Continuing Financing Activities |
|
10.85
-28.26%
|
15.12
+201.88%
|
5.01
+11823.81%
|
0.04
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
12.10
-29.84%
|
17.25
+244.96%
|
5.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.04
-58.82%
|
0.10
+1175.00%
|
0.01
-80.95%
|
0.04
|
| Net Other Financing Charges |
|
-1.30
+41.80%
|
-2.23
|
—
|
—
|
| Changes In Cash |
|
-0.13
-102.17%
|
5.98
+285.86%
|
-3.22
+70.21%
|
-10.80
|
| Beginning Cash Position |
|
7.15
+509.89%
|
1.17
-73.29%
|
4.39
-71.10%
|
15.19
|
| End Cash Position |
|
7.02
-1.82%
|
7.15
+509.89%
|
1.17
-73.29%
|
4.39
|
| Free Cash Flow |
|
-10.97
-20.12%
|
-9.14
+10.93%
|
-10.26
-16.42%
|
-8.81
|
| Interest Paid Supplemental Data |
|
0.02
-23.81%
|
0.02
+50.00%
|
0.01
|
—
|
| Income Tax Paid Supplemental Data |
|
0.00
-50.00%
|
0.00
-94.74%
|
0.04
|
—
|
| Change In Interest Payable |
|
—
|
—
|
—
|
—
|
| Common Stock Issuance |
|
12.10
-29.84%
|
17.25
+244.96%
|
5.00
|
0.00
|
| Issuance Of Capital Stock |
|
12.10
-29.84%
|
17.25
+244.96%
|
5.00
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-07 View
- 42026-04-07 View
- 42026-04-07 View
- 42026-04-07 View
- 8-K2026-03-30 View
- 10-K2026-03-30 View
- 42026-03-27 View
- 8-K2026-03-27 View
- 42026-03-24 View
- 42026-03-24 View
- 42026-03-24 View
- 8-K2026-03-23 View
- 8-K2026-02-06 View
- 42026-01-22 View
- 42026-01-05 View
- 42026-01-02 View
- 8-K2026-01-02 View
- 42025-12-22 View
- 42025-12-19 View
- 42025-12-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|